Technical Analysis for ARWR - Arrowhead Research Corporation
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Up | Down | Up |
Historical ARWR trend table... |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 0.00% | |
Bollinger Band Squeeze | Range Contraction | 0.00% | |
Inside Day | Range Contraction | 0.00% | |
Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -0.49% | |
New Uptrend | Bullish | -0.49% | |
Bollinger Band Squeeze | Range Contraction | -0.49% | |
BB Squeeze Started | Range Contraction | -0.49% | |
Up 3 Days in a Row | Strength | -0.49% | |
Up 4 Days in a Row | Strength | -0.49% | |
Crossed Above 20 DMA | Bullish | 0.71% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
Alert | Time |
---|---|
60 Minute Opening Range Breakdown | 1 day ago |
Down 1% | 1 day ago |
Up 2% | 1 day ago |
Rose Above Upper Bollinger Band | 1 day ago |
Up 1% | 1 day ago |
Get this analysis on your stocks daily!
- Earnings date: 05/05/2021
Arrowhead Research Corporation Description
Arrowhead Research Corporation operates as a clinical stage therapeutics company. It has development programs in oncology, obesity, and chronic hepatitis B virus (HBV) infection. The company assembles a set of technologies, including Dynamic Polyconjugate platform, a RNA delivery system that addresses multiple organ systems and cell types, promotes multi-log gene knockdown in rodents and non-human primates, and induces endosomal escape; and RONDEL, a RNA delivery system for systemic siRNA delivery, and RNAi-mediated mRNA and protein knockdown in human melanoma patients. It also offers Homing Peptides platform, a library of short peptides for the development of peptide-drug conjugates and companion diagnostics. The company's principal product candidates include Adipotide, an anti-obesity peptide, which is in Phase I clinical trial for disrupting the blood supply that supports unhealthy fat by the targeted induction of apoptosis (cell death) in the vasculature of adipose tissue; ARC-520, an RNAi-based therapeutic to treat chronic HBV infection; and CALAA-01, an RNAi-based therapeutic that has completed a Phase IB clinical trial, which targets solid tumors. Its products also comprise CRLX-101 for NSC lung cancer; and Tubulin Inhibitor for oncology. The company, formerly known as InterActive Group, Inc., was founded in 2003 and is headquartered in Pasadena, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biology Solid Tumors Organ Systems Genetics Molecular Biology Infection Melanoma Hepatitis B Gene Expression Library Obesity Peptides Hepatitis B Virus Companion Diagnostic RNA Rna Interference Biochemistry Chronic Hepatitis B Virus Molecular Genetics Apoptosis Chronic Hepatitis B Small Interfering Rna
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 92.6 |
52 Week Low | 30.83 |
Average Volume | 764,675 |
200-Day Moving Average | 61.53 |
50-Day Moving Average | 73.95 |
20-Day Moving Average | 65.23 |
10-Day Moving Average | 65.11 |
Average True Range | 3.56 |
ADX | 23.88 |
+DI | 21.77 |
-DI | 21.04 |
Chandelier Exit (Long, 3 ATRs ) | 62.69 |
Chandelier Exit (Short, 3 ATRs ) | 71.21 |
Upper Bollinger Band | 69.92 |
Lower Bollinger Band | 60.53 |
Percent B (%b) | 0.76 |
BandWidth | 14.40 |
MACD Line | -1.74 |
MACD Signal Line | -2.64 |
MACD Histogram | 0.9051 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 71.01 | ||||
Resistance 3 (R3) | 71.24 | 70.36 | 70.45 | ||
Resistance 2 (R2) | 70.36 | 69.50 | 70.24 | 70.26 | |
Resistance 1 (R1) | 69.00 | 68.97 | 68.56 | 68.77 | 70.08 |
Pivot Point | 68.12 | 68.12 | 67.90 | 68.00 | 68.12 |
Support 1 (S1) | 66.76 | 67.26 | 66.32 | 66.53 | 65.22 |
Support 2 (S2) | 65.88 | 66.73 | 65.76 | 65.04 | |
Support 3 (S3) | 64.52 | 65.88 | 64.85 | ||
Support 4 (S4) | 64.29 |